|1.||Soares, Kevin C: 1 article (02/2014)|
|2.||Pawlik, Timothy M: 1 article (02/2014)|
|3.||Herman, Joseph M: 1 article (02/2014)|
|4.||Kamel, Ihab: 1 article (02/2014)|
|5.||Cosgrove, David P: 1 article (02/2014)|
|6.||Tanaka, H: 1 article (10/2010)|
|7.||Ioka, A: 1 article (10/2010)|
|8.||Tsukuma, H: 1 article (10/2010)|
|9.||Nakahara, T: 1 article (10/2010)|
|10.||Tanaka, M: 1 article (10/2010)|
|1.||Primary sclerosing cholangitisIBA
02/01/2014 - "A variety of risk factors have been associated with HC, most notably primary sclerosing cholangitis (PSC), biliary stone disease and parasitic liver disease. "
10/01/2010 - "There are several established risk factors for intrahepatic cholangiocarcinoma (ICC), namely primary sclerosing cholangitis, fibropolycystic liver disease, parasitic infection, intrahepatic biliary stones and chemical carcinogen exposure. "
|4.||Antipyrine (Phenazone)FDA Link
09/01/1994 - "Alveolar echinococcosis (AE), an uncommon and very severe parasitic liver disease, can be considered as an "infectious model" of granulomatous disease, where cellular immunity plays a key role in the defence against Echinococcus multilocularis, the larval cestode responsible for the disease. "